Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q3 FY2022 Earnings Presentation
25 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, February 2022
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q3FY22
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q3FY22 February 2022
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Key Highlights
Key Highlights Team size of 2,300+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 5: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 6: Experienced Independent Directors
Experienced Independent Directors Rajender Mohan Malla Dr. Sandhya Mehta Harpal Singh (Chairman and Independent (Independent Director) (Independent Director) Director) • Mr. Rajender has very distinguished career • Dr. Sandhya is working as the principal of • Mr. Harpal has had over 35 year's of fou
Slide 7: Our Journey
Our Journey Unit-08 & Unit- Unit-06 for Conversion of Commencement 10* for Multi Pantoprazole Unit-2 as Dedicated of Unit-02 for USFDA, EIR for Products 2020 (Dedicated) 2018 facility for Ibuprofen 2016 2013 Multi Product Ibuprofen Unit-07 Metformin Unit-04 Metformin Unit-03 for new Received EUGMP 2
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA Ibuprofen EUGMP Certification in Certificate of Suitability Certificate of Suitability facility since 2015, 2013, 2017 & from EDQM for from EDQM for recertified in 2019 Recertification in 2020 IBUPROFEN, CEP No. 316- LAMOTRIGINE, CEP No. 2008 066-2013
Slide 9: Product Segmentation
Product Segmentation 9
Slide 10: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added 8 new products in Product portfolio that producer of Metf
Slide 11: Pharmaceuticals Product Portfolio – Commercialized & Pipeline
Pharmaceuticals Product Portfolio – Commercialized & Pipeline API - Commercialized API - Pipeline Ibuprofen Fexofenadine Ibuprofen Lysinate Quetiapine Fumarate Ibuprofen Sodium Dextromethorphan Dex-Ibuprofen Metformin HCL Apixaban Clopidogrel Bisulphate (Form II) Alluprinol Pantoprazole Sodium Fenof
Slide 12: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 13: Product wise Segmentation – Quarterly
Product wise Segmentation – Quarterly Q3FY22 Q2FY22 Q3FY21 555 538 513 81 60 96 (12%) (15%) (17%) 209 299 299 (41%) 157 (56%) (54%) 243 160 (29%) (47%) (29%) Chemicals Ibuprofen Other API’s 13 All figures in INR crs unless stated
Slide 14: Product wise Segmentation – 9 Months
Product wise Segmentation – 9 Months 9MFY22 9MFY21 1612 1506 155 239 (10%) (15%) 556 904 (37%) 469 (56%) (29%) 795 (53%) Chemicals Ibuprofen Other API’s 14 All figures in INR crs unless stated
Slide 15: Manufacturing Facility spread across over 111 acres with GMP approved guidelines
Manufacturing Facility spread across over 111 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum utilization of resources and • Primary healthcare including s
Slide 17: Financial Overview
Financial Overview 17
Slide 18: Key Financial Summary
Key Financial Summary Financial Summary Q3FY22 Q2FY22 Q3FY21 9M FY22 9M FY21 (INR Cr) Total Income 564 548 521 1,637 1,525 Gross Profit 163 143 234 495 700 EBITDA 68 54 165 238 499 PAT 40 31 115 138 369 18 All Profits and Total Income include Other Income
Slide 19: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000 1,910 1,991 50% 50% Gross % 1,800 1,696 45% 45% 45% 45% 12% 1,600 44% 40% 40% EBITDA % 1,400 33% 38% 31% 31% 35% 35% 33% 30% 31% 1,200 25% 30% 30% 16% 990 22% PAT % 22% 1,000 25% 25% 19% 80
Slide 20: Quarterly & 9 Monthly Financial Performance
Quarterly & 9 Monthly Financial Performance Quarterly Revenues & Margins* 9 Months Revenues & Margins* 570 45% 564 50% 1850 46% 50% 45% 1637 45% 550 548 1650 40% 1525 40% 32% 35% 1450 30% 35% 530 29% 521 26% 30% 33% 30% 1250 510 25% 25% 20% 1050 24% 20% 22% 15% 490 12% 15% 15% 10% 850 470 10% 10% 65
Slide 21: Geographical Segmental Breakup – Annual, 9 Month & Quarter
Geographical Segmental Breakup – Annual, 9 Month & Quarter Annually 9 Monthly Quarterly In INR crs In INR crs In INR crs 1354 1250 1244 1038 1037 38% 34% 31% 633 647 644 613 31% 40% 484 36% 470 412 396 32% 350 368 363 26% 26% 29% 227 143 142 150 FY17 FY18 FY19 FY20 FY21* 9MFY22 9MFY21 Q3FY22 Q2FY22
Slide 22: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY17 FY18 FY19 FY20 FY21 H1 FY22 Shareholder's Funds 188.7 215.7 474.3 813.5 1260.4 1345.4 Debt 446.5 421.9 284.0 56.0 0.0 0.0 Other Long Term Liabilities 17.2 33.6 20.8 79.7 59.1 59.0 Other Current Liabilities 165.1 180.9 162.8 220.6 290.6 3
Slide 23: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 FY21 Q3FY22 Q2FY21 Q3FY21 9M FY22 9M FY21 Revenues 710.6 983.3 1,685.3 1,894.5 1,967.0 555.1 537.9 513.0 1611.5 1506.6 Other Income 1.3 6.3 10.4 16.0 24.3 8.9 10.5 7.8 25.1 18.1 Total Income 711.9 989.6 1,695.7 1,910.
Slide 24: Shareholding Information
Shareholding Information Stock Data (As on 31st December, 2021) Shareholding Pattern (%) Market Capitalization (₹) 2,837 Crs 52.9% 48.5% Face Value(₹) 10 43.7% 43.7% Share Price (₹) 483.4 EPS TTM (₹) 36.3 52-Week High (₹) 738.5 7.8% 3.4% 52-Week Low (₹) 424.2 Promoter Institutional Non-institutional
Slide 25: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Q3 FY2022 Earnings Presentation on 6ix